mynth
07/2021100%

Nutraq acquired by Orkla

NORWAY Life Sciences / Nutrition & Dietary Supplements EV NOK 1–10bn

Context

Orkla completed its acquisition of NutraQ to strategically enhance its presence in high-growth market segments, specifically the health category and the direct-to-consumer (D2C) channel. The transaction provides Orkla with a new, subscription-based business model, diversifying its traditional go-to-market strategies and offering exciting growth opportunities. Orkla's leadership expressed admiration for the target's successful use of subscription solutions to build a significant customer base with direct home delivery. The strategic plan involves continuing the development of NutraQ's established concepts while simultaneously exploring new possibilities for applying the D2C model across Orkla's broader portfolio. To preserve the target's unique competencies and entrepreneurial culture, NutraQ will continue to operate as a stand-alone entity within the Orkla Care business area, with its existing executive management team remaining in place. The deal represents a logical next step for NutraQ, transitioning it from private equity ownership under Impilo and Sana Pharma Holding to a long-term industrial owner poised to support its next phase of growth and expansion. The transaction received all necessary approvals from relevant competition authorities prior to its completion.

Nutraq, which reported an EBITDA margin of [members only] in 2020, is valued in this transaction at an EV/EBITDA multiple of 15x–25x.

-> Deep-dive in Healthcare & Pharma market trends

Target

NutraQ is a prominent supplier specializing in subscription-based health and wellness products, primarily serving the Nordic market. Established in Norway in 2002, the company has since expanded its operational footprint to include Denmark, Finland, Sweden, the Czech Republic, Slovakia, the Netherlands, and Poland. Despite this expansion, the four Nordic countries consistently constitute the vast majority of its turnover. The company's core business model is centered on a direct-to-consumer (D2C) approach, leveraging subscription services to deliver a range of health and wellness concepts directly to customers' homes. This model has proven successful, supporting significant organic growth in its customer base; in the period 2018-2020, the number of active subscriptions grew by an average of 13 percent per year. Headquartered in Oslo, Norway, NutraQ operates with a dedicated team of approximately 170 employees. The company's strategy focuses on building and maintaining strong customer relationships through its recurring revenue model and continuously developing attractive product offerings within the health and wellness space. Its well-established platform is designed to support further growth and geographic expansion.

Ent. Value

NOK 1–10bn

Equity Value

[members only]

Multiples

EV / Revenue

2x–6x

EV / EBITDA

15x–25x

EV / EBIT

[members only]

Historical Financials (NOK)

Year
Rev
EBITDA
EBIT
2020
NOK 450–900M
NOK 100–200M
[members only]
2019
NOK 450–900M
NOK 100–200M
[members only]

Other operations with Orkla

Other operations with Orkla
DateAcquirerTargetCountrySector
07/2026ORKLATHE EUROPEAN CANDY GROUPNETHERLANDSFood Products
05/2026ORKLAPHOENIX BRANDSUNITED KINGDOMFood Products
10/2022ORKLADENALI INGREDIENTSUNITED STATESIngredients

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
11/2021ESSLING CAPITAL / MULTICROISSANCE / BOURRELIER GROUPTEKNIMEDFRANCEImplants & Prosthetics
09/2021PERRIGO COMPANYHRA PHARMAFRANCEGenerics / Labs
07/2021MONTAGU PRIVATE EQUITYINTECH MEDICALFRANCEImplants & Prosthetics
07/2021PARTNERS GROUPPHARMATHENGREECECDMO
04/2021NESTLETHE BOUNTIFUL COMPANYUNITED STATESNutrition & Dietary Supplements
04/2021NAXICAP PARTNERSLAGARRIGUEFRANCEImplants & Prosthetics
04/2021DIASORINLUMINEX CORPORATIONUNITED STATESDiagnostic Equipment
03/2021CVCCOOPER-VEMEDIAFRANCEGenerics / Labs
02/2021IK PARTNERSINNOVAD GROUPBELGIUMAnimal Health
02/2021SIPAREXWINNCAREFRANCEMedical Devices

REFERENCES

Valuation range: EV NOK 1–10bn

Revenue range: NOK 450–900M

EBITDA range: NOK 100–200M

EV/Revenue range: 2x - 6x

EV/EBITDA range: 15x - 25x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Nutraq by Orkla are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: nutraq

FAQ

What transaction does this page cover?

This page covers Orkla’s acquisition of 100% of Nutraq, a Norwegian company specialised in Nutrition & Dietary Supplements, in 2021.

How was the acquisition of Nutraq by Orkla valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the NOK 1–10bn band, its EV/EBITDA multiple within the 15x - 25x range, and its EV/revenue multiple within the 2x - 6x range. Exact figures are available to members.

What were Nutraq’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Nutraq generated annual revenue estimated in the NOK 450–900M range and EBITDA in the NOK 100–200M bracket (FY 2020). Detailed financial figures are available to members.

What sources support the information on this transaction?

The details of this transaction are sourced directly from the official corporate announcement published on the parties’ institutional website, ensuring primary-source verification of the closing and perimeter.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.